Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes
of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, opportunities, risks, initiatives,
growth, strategies, product offerings, sales force, consumers and new product development; statements regarding shareholder value and projections regarding our 2015-2016
business cycle, future sales, expenses, earnings per share, sources and uses of cash, foreign currency fluctuations, inventory and other financial items; statements of management's
expectations and beliefs regarding China and other markets; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify
these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the
negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking
statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

risk that continuing media and regulatory scrutiny and investigations in China, and any actions taken by the company or by regulators, could cause unanticipated complications
or other difficulties, make it more difficult to forecast results for future periods, and could negatively impact the company's revenue, sales force and business in this market,
including the interruption of sales activities, loss of licenses, and the imposition of fines, and any other adverse actions or events;

risks related to negative publicity regarding recent media allegations and subsequent regulatory investigations and fines;

risk that direct selling regulations in China may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or the
imposition of a range of potential penalties;

any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a
sustained basis;

risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support the company's planned initiatives or launch strategies, and increased
risk of inventory write-offs if the company over-forecasts demand for a product, changes its planned initiatives or launch strategies, or does not achieve expected sales levels;

risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;

unpredictable economic conditions and events globally;

regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a
product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;

adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;

any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States and any adverse results of tax
audits or unfavorable changes to tax laws in the company's various markets; and

continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents
filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first
provided and the company assumes no duty to update the forward-looking statements contained herein to reflect any change except as required by law.

10

11

Beat Guidance
Within Range
Missed Guidance

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014
projected

12

2 reasons for 2014

China business disruption
Regional TR90 launches

13

14

*
1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
*projected

15

2014
projected

2015

2016

2017

2018

2019

2020
16

2014
projected

2015

2016

2017

2018

2019

2020
17

18

ANTI-AGING PRODUCTS AND SERVICES: THE GLOBAL MARKET, BCC RESEARCH, AUGUST 2013

19

A GLOBAL PERSPECTIVE ON DIRECT SELLING, BEAUTY & PERSONAL CARE AND CONSUMER HEALTH, EUROMONITOR INTERNATIONAL, MARCH 2014

20

A GLOBAL PERSPECTIVE ON DIRECT SELLING, BEAUTY & PERSONAL CARE AND CONSUMER HEALTH, EUROMONITOR INTERNATIONAL, MARCH 2014

21

22

SOURCE: WFDSA Global Direct Selling Statistics

23

Source: Direct Selling News

24

25

26

27

28

29

30

31

32

33

PRODUCT FORMULATION

INGREDIENT LIBRARY

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

INTRODUCTION OF AGELOC IN EXISTING CATEGORIES

68

INTRODUCTION OF AGELOC INTO FIRST PHARMANEX PRODUCT

AND FURTHER DEVELOPMENT OF AGELOC GALVANIC IN
SKINCARE

69

EXPANSION INTO WEIGHT MANAGEMENT AND BODY SHAPING

CATEGORYAGELOC TR90

70

71

72

73

74

75

76

77

78

79

80

81

82

83

87

88

89

90

Estimates based on company releases and statements in the media

91

92

Millions USD

93

94

95

96

97

98

99

100

101

102

103

104

105

106

Millions USD

5 Yr. CAGR = 14%

3 Yr. CAGR = 14%

107

Millions USD

5 Yr. CAGR = 13%

3 Yr. CAGR = 13%

108

Millions USD

5 Yr. CAGR = 15.0%

3 Yr. CAGR = 19.1%

109

1,200,000

1,600,000

1,000,000

1,200,000

Thousands USD

Thousands USD

1,400,000

5 Yr. CAGR = 36%

3 Yr. CAGR = 41%

1,000,000
800,000
600,000

5 Yr. CAGR = 61%

3 Yr. CAGR = 67%

800,000
600,000

400,000

400,000
200,000
200,000
0

0
2009

2010

2011

2012

2013

2014

2009

2010

2011

2012

2013

2014
110

Thousands Won

500,000,000

5 Yr. CAGR = 22%

3 Yr. CAGR = 17%

400,000,000
300,000,000
200,000,000

5 Yr. CAGR = -5%

3 Yr. CAGR = -3%

50,000,000
45,000,000
40,000,000

Thousands Yen

600,000,000

35,000,000
30,000,000
25,000,000
20,000,000

15,000,000
10,000,000

100,000,000

5,000,000
0

0
2009 2010 2011 2012 2013 2014

2009

2010

2011

2012

2013

2014
111

$400
$350

16%

19%

27%
8%

Millions USD

9%

5 Yr. CAGR = 22%

3 Yr. CAGR = 10%

$300

$250
$200
$150

$100
21%

$50
$0

Singapore
Thailand
Indonesia

Malaysia
Australia/New Zealand
Philippines & Other

2009

2010

2011

2012

2013

2014

112

$70

5 Yr. CAGR = 24%

3 Yr. CAGR = 43%

$350
$300

Millions USD

$60

Millions USD

5 Yr. CAGR = 3%
3 Yr. CAGR = 6%

$50
$40

$30

$250
$200
$150

$20

$100

$10

$50

$0

$0
2009

2010

2011

2012

2013

2014

2009

2010

2011

2012

2013

2014
113

$250

5 Yr. CAGR = 6%
3 Yr. CAGR = 4%

12%

40%

18%

Millions USD

$200

$150

$100

30%
$50

West Europe
East Europe

North Europe
Russia/Other

$0
2009

2010

2011

2012

2013

2014
projected
114

AMERICAS
+7 - 10%

EMEA
(3 5)%

GREATER
CHINA
+2 - 5%

NORTH
ASIA
+5 - 8%

SOUTH ASIA /
PACIFIC
+8 - 10%
Global Local-Currency Growth

Expected Currency Impact

4 - 6%

-6%

115


116

117

*Excludes certain items- see GAAP reconciliation table.

118

*Excludes certain items- see GAAP reconciliation table.

119

120

121

122

EARNINGS PER SHARE

*Excludes certain items- see GAAP reconciliation table.

123

124

125

126

127

128

129

$1.38
$1.20

$0.80
$0.59

$0.20

$0.24

$0.28

$0.32

$0.36

$0.40

$0.42

$0.44

$0.46

$0.50

130

131

132

133

Financial Information in this Presentation

For simplicity, graphs and growth calculations related to 2014 reflect the mid-point 2014 projections that
we provided in our last earnings call.
For years 2009 and later, revenue and selling expense have been adjusted to reflect the correct
classification of certain selling rebates. Revenue and selling expense for years prior to 2009 have not
been similarly adjusted, as we do not believe the adjustments are material.
This presentation contains non-GAAP financial information. Management believes these non-GAAP
financial measures assist management and investors in evaluating, and comparing from period to period,
results from ongoing operations in a more meaningful and consistent manner while also highlighting more
meaningful trends in the results of operations. A reconciliation of non-GAAP measures presented in this
presentation is provided on the GAAP reconciliation slide that follows.

134

GAAP Reconciliation
81.9%
0.0%
0.0%

81.5%
0.0%
0.0%

81.2%
1.9%
0.0%

Projected
2014
81.4%
0.0%
2.0%

81.9%

81.5%

83.1%

83.4%

6.1%
1.7%
0.0%

11.2%
0.8%
0.0%

13.6%
0.0%
1.9%

13.4%
0.0%
0.0%
2.0%

7.8%

12.0%

15.5%

15.4%

2007
Gross Margin
Percentage impact of Japan customs ruling
Percentage impact of inventory reserve
Gross Margin excluding Japan customs ruling and inventory
reserve
Operating Margin
Percentage impact of restructuring
Percentage impact of Japan customs ruling
Percentage impact of inventory reserve
Operating Margin excluding restructuring, Japan customs ruling and
inventory reserve
Earnings per share
Impact of restructuring
Impact of Japan customs ruling
Impact of inventory reserve
Impact of Venezuela Highly Inflationary accounting
Earnings per share excluding restructuring, Japan customs ruling,
inventory reserve and Venezuela highly inflationary accounting.

-2.0% to 0.0%
-6.0%
4.0% to 6.0%

2011

0.67
0.17
-

1.40
0.11
-

2.38
0.31
-

3.06 - 3.11
0.52
0.48

0.84

1.51

2.69

4.06 - 4.11

Projected 2015 Range

Revenue
Growth
FX Impact
Local-Currency
Revenue
Growth

2009

Revenue - Less LTO

LTO Revenue
Revenue
FX Impact
Local-Currency
Revenue using 2009
FX Rates

2009
1,297
17
1,314
-

2010
1,463
55
1,518
(69)

2011
1,610
110
1,720
(155)

1,314

1,449

1,565

1,832
300
2,132
(154)

2013
2,627
550
3,177
(127)

Projected
2014
2,350
210
2,560
81

1,978

3,050

2,641

2012